Ignite Creation Date:
2024-05-05 @ 6:33 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00503204
Status:
COMPLETED
Last Update Posted:
2009-11-25
First Post:
2007-07-16
Brief Title:
Phase I Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Organization Data
Organization:
AstraZeneca
Class:
INDUSTRY
Study ID:
D8480C00057
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
AstraZeneca
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Jane Robertson Medical Science Director
Old Organization:
AstraZeneca